Combination Imaging May Improve Breast Tumor Differentiation

Share this content:
Combination Imaging May Improve Breast Tumor Differentiation
Combination Imaging May Improve Breast Tumor Differentiation

(HealthDay News) -- Use of multiparametric 18fluorodeoxyglucose positron emission tomography magnetic resonance imaging (MP 18FDG PET-MRI) using dynamic contrast-enhanced MRI (DCE-MRI), diffusion-weighted imaging, three-dimensional proton MR spectroscopic imaging, and 18FDG-PET can improve differentiation of benign and malignant breast tumors, according to a study published online in Clinical Cancer Research.

Katja Pinker, MD, from the Medical University of Vienna, and colleagues examined whether MP 18FDG PET-MRI improves differentiation of benign and malignant breast tumors using data from 76 women with an imaging abnormality.

RELATED: Breast Cancer Resource Center

Participants underwent fused PET-MRI of the breast. The likelihood of malignancy was compared for all single parameters, for MP MRI with two/three parameters, and for MP 18FDG PET-MRI, with histopathology as the standard of reference.

The researchers found that the area under the curve (AUC) was significantly higher with MP 18FDG PET-MRI than with DCE-MRI (0.935 vs. 0.86; P = 0.044) and compared with the combination of DCE-MRI and a second parameter (AUC, 0.761 to 0.826; P = 0.013 to 0.020). Further slight improvements were seen for MP 18FDG PET-MRI compared with MP MRI with three parameters (AUC, 0.925; P = 0.317). Compared with use of MP imaging with one or two parameters, MP 18FDG PET-MRI would be associated with a reduction in unnecessary breast biopsies (P = 0.002 to 0.011).

"This feasibility study shows that MP 18FDG PET-MRI enables an improved differentiation of benign and malignant breast tumors when several MRI and PET parameters are combined," the researchers wrote. "MP 18FDG PET-MRI may lead to a reduction in unnecessary breast biopsies."


  1. Pinker K, Bogner W, Baltzer P, et al. Improved Differentiation of Benign and Malignant Breast Tumors with Multiparametric 18Fluorodeoxyglucose Positron Emission Tomography Magnetic Resonance Imaging: A Feasibility Study. Clin Cancer Res. 2014;doi:10.1158/1078-0432.CCR-13-2810.

Related Resources

Related Slideshows

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs